Kivexa

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2017
02420052017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND The objective of this study was to determine the impact of tenofovir or abacavir discontinuation on low-density… (More)
  • table 1
  • figure 1
Is this relevant?
2017
2017
Background Switching from PIs to dolutegravir in virologically suppressed HIV-infected individuals has not been assessed… (More)
Is this relevant?
2011
2011
combined with Truvada (emtricitabine/ tenofovir). However, there is very limited data on the efficacy of NVP + Kivexa, which… (More)
  • table 1
Is this relevant?
2010
2010
BACKGROUND Although efavirenz and lopinavir/ritonavir(r) are both recommended antiretroviral agents in antiretroviral-naïve HIV… (More)
  • table 1
  • figure 1
  • figure 4
  • figure 3
Is this relevant?
2010
2010
BACKGROUND Although antiretroviral therapy improves immune response, some human immunodeficiency virus-infected patients present… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
Is this relevant?
2010
2010
Background Dyslipidemia in persons with HIV contributes significantly to cardiovascular (CV) risk. Abacavir (ABC) has been shown… (More)
  • figure 1
Is this relevant?
2010
2010
Methods Data was collected as part of ROCKET 1, a Phase 4, open-label, randomised, UK, multicentre, controlled study. At baseline… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Table of contents 1.0 Introduction 2.0 Methodology 2.1 Basing recommendations on evidence 2.2 Implications for research 2.3 Use… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2008
2008
BACKGROUND Patients prefer fewer pills and once-daily (qd) dosing without food restrictions. We assessed the impact on adherence… (More)
Is this relevant?
2005
2005
BACKGROUND Abacavir (ABC) and lamivudine (3TC) administered twice daily were compared with an ABC + 3TC fixed-dose combination… (More)
Is this relevant?